Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma-Reference-Cited by-同舟云学术

Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma

Published:2020-02-28 Issue:6 Volume:189 Page:1074-1082
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chakraborty Rajshekhar¹^ORCID,Rybicki Lisa¹,Nakashima Megan O.¹,Dean Robert M.¹,Faiman Beth M.¹,Samaras Christy J.¹,Rosko Nathaniel²,Dysert Hayley¹,Valent Jason¹,Anwer Faiz¹

Affiliation:

1. Taussig Cancer Center Cleveland Clinic Cleveland OH USA

2. Department of Pharmacy Cleveland Clinic Cleveland OH USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16488

Reference16 articles.

1. Role of natural and immune IgM antibodies in immune responses

2. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

3. Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation

4. Immunological factors and risk of infection in plateau phase myeloma.

5. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why do patients with cancer die?;Nature Reviews Cancer;2024-06-19

2. Development of a nomogram prognostic model for early Grade ≥ 3 infection in newly diagnosed multiple myeloma based on immunoparesis;International Immunopharmacology;2024-01

3. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial;British Journal of Haematology;2023-09-10

4. Low-Grade B-cell Malignancy with M-Protein and Autoimmune Cytopenia;The Kitakanto Medical Journal;2022-11-01

5. Clinical Considerations for Immunoparesis in Multiple Myeloma;Cancers;2022-05-03